1634 related articles for article (PubMed ID: 24191305)
1. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
3. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
[TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
[TBL] [Abstract][Full Text] [Related]
6. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
7. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
9. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.
Mann JF; Anderson C; Gao P; Gerstein HC; Boehm M; Rydén L; Sleight P; Teo KK; Yusuf S;
J Hypertens; 2013 Feb; 31(2):414-21. PubMed ID: 23249829
[TBL] [Abstract][Full Text] [Related]
12. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
[TBL] [Abstract][Full Text] [Related]
13. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
[TBL] [Abstract][Full Text] [Related]
14. [Critically appraised article].
Neumann I; Grassi B
Rev Med Chil; 2012 Jan; 140(1):117-20. PubMed ID: 22552566
[TBL] [Abstract][Full Text] [Related]
15. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan for the management of patients at high cardiovascular risk.
Ruilope LM
Curr Med Res Opin; 2011 Aug; 27(8):1673-82. PubMed ID: 21718097
[TBL] [Abstract][Full Text] [Related]
18. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.
Kurnik D; Vesterman-Landes J; Bialik M; Katzir I; Lomnicky Y; Halkin H; Loebstein R
Clin Ther; 2011 Apr; 33(4):456-64. PubMed ID: 21635991
[TBL] [Abstract][Full Text] [Related]
19. Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
Chen SS; Seliger SL; Fried LF
Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):449-55. PubMed ID: 25014549
[TBL] [Abstract][Full Text] [Related]
20. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
